Welcome to our dedicated page for Aurinia Pharmaceuticals news (Ticker: $AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aurinia Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aurinia Pharmaceuticals's position in the market.
A shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has urged the Board of Directors to take action to enhance shareholder value. The shareholder, Lucien Selce, expressed concerns about the Company's current strategy, Board composition, and market penetration. He outlined the need for restructuring the Board, setting clear objectives for market penetration, and developing strategic partnerships to improve performance and shareholder value.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will attend the 2024 RBC Capital Markets Global Healthcare Conference in New York from May 14-15, 2024. Management will host one-on-one meetings with investors and participate in a fireside chat. A live webcast of the session will be available on the company's website.
Aurinia Pharmaceuticals Inc. reported $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, with a year-over-year growth of approximately 46% and 40% respectively. The company achieved significant milestones like FDA approval for LUPKYNIS and plans to reach positive free cash flows in Q2 2024. The 2024 net product revenue guidance is $200 to $220 million. Financially, total net revenue increased, operating expenses decreased, and the company maintained a strong liquidity position.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reaffirms its commitment to raising awareness about lupus nephritis (LN) during Lupus Awareness Month. The company is engaging in various education initiatives to improve understanding, screening, and management of LN. Through partnerships and advocacy efforts, Aurinia aims to eliminate barriers to access, promote equity, and enhance health outcomes for individuals affected by LN.
The FDA has approved an updated label for LUPKYNIS, a drug by Aurinia Pharmaceuticals (NASDAQ: AUPH), including long-term data from the AURORA Clinical Program, showing sustained complete renal response through three years. The label now indicates that monthly kidney function assessment is no longer required after the first year of treatment. The safety profile of LUPKYNIS remains unchanged and aligns with the AURORA clinical program's findings.
